Γ
Content Highlights || Full Agenda
Breakout Session

3:30 PM

-

4:15 PM

Biomanufacturing

Beyond Batch: What Will Unlock the Next Generation of Fermentation?

Conventional batch fermentation has long been the backbone of industrial biotechnology — but a new wave of platforms is challenging that paradigm. From continuous and gas fermentation and novel feedstock integration to the emerging role of AI across the stack, Industrial Biotech is changing at a rapid pace. So what's actually holding them back, and what will it take to move them forward? This panel brings together practitioners and innovators working at the frontier of alternative fermentation systems to explore the enablers, accelerators, and real-world lessons shaping the path ahead. Rather than debating which technology "wins," we'll examine the shared challenges across platforms: navigating the pilot-to-commercial scale-up journey, working with non-traditional feedstocks, and incorporating new AI tools into the process. Whether you're deep in the lab or making investment and deployment decisions, this conversation will surface concrete insights on what's needed — technically, operationally, and systemically — to unlock the next generation of fermentation.

Breakout Session

3:30 PM

-

4:15 PM

Biomanufacturing

Beyond Batch: What Will Unlock the Next Generation of Fermentation?

Conventional batch fermentation has long been the backbone of industrial biotechnology — but a new wave of platforms is challenging that paradigm. From continuous and gas fermentation and novel feedstock integration to the emerging role of AI across the stack, Industrial Biotech is changing at a rapid pace. So what's actually holding them back, and what will it take to move them forward? This panel brings together practitioners and innovators working at the frontier of alternative fermentation systems to explore the enablers, accelerators, and real-world lessons shaping the path ahead. Rather than debating which technology "wins," we'll examine the shared challenges across platforms: navigating the pilot-to-commercial scale-up journey, working with non-traditional feedstocks, and incorporating new AI tools into the process. Whether you're deep in the lab or making investment and deployment decisions, this conversation will surface concrete insights on what's needed — technically, operationally, and systemically — to unlock the next generation of fermentation.

SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.

The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.

Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.

“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”

Eric Schmidt

Former CEO

"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."

Celestine Schnugg

Founder

"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."

Surge Biswas

Founder

"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."

Jacob Glanville

Founder & CEO

"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."

Bill Tai

Co-founder

"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira

Head of Digital Biology

"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."

Ola Wlodek

CEO

Who’s Coming to SynBioBeta?

And the BD and R&D Leads
That Will Be Your Customers and Partners: